A Phase 3 interventional study of Insulin Glargine and LY2189265 in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 78 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-01-16.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 6th largest by enrollment, is one of 7 that started in 2010, is one of 22 in phase 3, and was the 6th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Mexico
Ages 10–17
First Affiliated Hospital of Wannan Medical College
Ages 18+
Seoul National University Bundang Hospital
Ages 20–90
By country, each count listing its studies:
dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 6 · Phase 3 23 · Phase 4 9
First in 2008; this study’s year is marked. 7 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 810 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 159 across the 54 interventional studies. Of the 47 that completed or were terminated, 38 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 54 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 34th largest by enrollment of the 232 interventional ones that give a count, is one of 16 that started in 2010, is one of 85 in phase 3, and was the 45th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
1 of the studies testing dulaglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07537088First Affiliated Hospital of Wannan Medical CollegeEfficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if LY2189265 is effective in reducing hemoglobin A1c (HbA1c) and safe, as compared to Insulin Glargine in participants with Type 2 Diabetes. Participants must also be taking metformin and glimepiride.
Rescue therapy refers to 1 of 2 types of additional therapy, each given for a different reason: any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation. Participants who received rescue therapy were included in the analysis population, but only measurements obtained prior to the beginning of rescue therapy were included in specified efficacy analyses.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Type 2 Diabetes not well controlled on 1, 2, or 3 oral antidiabetic medications (at least one of them must be metformin and/or a sulfonylurea)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 78 weeks Metformin: at least 1500 milligrams per day (mg/day), oral, for 78 weeks Glimepiride: at least 4 mg/day, oral, for 78 weeks
Drug: LY2189265 · Drug: Metformin · Drug: Glimepiride
LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 78 weeks Metformin: at least 1500 milligrams per day (mg/day), oral, for 78 weeks Glimepiride: at least 4 mg/day, oral, for 78 weeks
Drug: LY2189265 · Drug: Metformin · Drug: Glimepiride
Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 78 weeks Metformin: at least 1500 milligrams per day (mg/day), oral, for 78 weeks Glimepiride: at least 4 mg/day, oral, for 78 weeks
Drug: Insulin Glargine · Drug: Metformin · Drug: Glimepiride
Also known as: Dulaglutide
Change From Baseline to 52 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)
Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline HbA1c as a covariate.
Time frame: Baseline, 52 weeks
Change From Baseline to 26 Weeks and 78 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)
Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline HbA1c as a covariate.
Time frame: Baseline, 26 weeks, and 78 weeks
Number of Participants Achieving Glycosylated Hemoglobin (HbA1c) Less Than 7% at 26, 52 and 78 Weeks
Number of participants achieving HbA1c levels less than 7.0% was analyzed with a logistic regression model with baseline, country, and treatment as factors included in the model.
Time frame: 26, 52, and 78 weeks
Number of Participants Achieving Glycosylated Hemoglobin (HbA1c) Less Than or Equal to 6.5% at 26, 52 and 78 Weeks
Number of participants achieving HbA1c levels less than or equal to 6.5% was analyzed with a logistic regression model with baseline, country, and treatment as factors included in the model.
Time frame: 26, 52, and 78 weeks
Change From Baseline to 26, 52 and 78 Weeks for Daily Mean Blood Glucose Values From the 8-point Self-monitored Blood Glucose (SMBG) Profiles
The self-monitored blood glucose (SMBG) data were collected at the following 8 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening meal; 2 hours post-evening meal; bedtime; and 3 AM or 5 hours after bedtime. Least Squares (LS) means of the mean of the 8 time points (Daily Mean) were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
Time frame: Baseline, 26, 52, and 78 weeks
Change From Baseline to 52 and 78 Weeks in Updated Homeostasis Model Assessment of Beta-cell Function (HOMA2-%B) and Updated Homeostasis Model Assessment of Insulin Sensitivity (HOMA2-%S)
The homeostatic model assessment (HOMA) is a method used to quantify insulin resistance and beta (β)-cell function. HOMA2-B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady state beta cell function (%B) as a percentage of a normal reference population (normal young adults). HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S), as percentages of a normal reference population (normal young adults). The normal reference population for both HOMA2-B and HOMA-2S were set at 100%. Least Squares (LS) means of change from baseline of C-peptide based HOMA2-%B and HOMA2-%S were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
Time frame: Baseline, 52, and 78 weeks
Change From Baseline to 52 and 78 Weeks in Glucagon Concentration
Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.
Time frame: Baseline, 52, and 78 weeks
Change From Baseline to 26, 52 and 78 Weeks for Body Weight
Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.
Time frame: Baseline, 26, 52, and 78 weeks
Change From Baseline to 26, 52 and 78 Weeks for Body Mass Index
Body mass index (BMI) is an estimate of body fat based on body weight divided by height squared. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
Time frame: Baseline, 26, 52, and 78 weeks
Change From Baseline to 26, 52 and 78 Weeks in the EuroQol 5 Dimension
The European Quality of Life - 5 dimensions (EQ-5D) questionnaire is a generic, multidimensional, health-related, quality-of-life instrument. It consists of 2 parts: the first part assesses 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that have 3 possible levels of response (no problem, some problem, or extreme problem). These dimensions are converted into a weighted health-state Index Score. The EQ-5D United Kingdom (UK) score ranges from -0.59 to 1.0, where a score of 1.0 indicates perfect health and negative values are valued as worse than dead. The second part of the questionnaire consists of a 100-mm visual analog scale (VAS) on which the participants rated their perceived health state on that day from 0 (worst imaginable health state) to 100 (best imaginable health). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) and adjusted by treatment, country, and baseline.
Time frame: Baseline, 26, 52, and 78 weeks
Change From Baseline to 26, 52 and 78 Weeks in the Impact of Weight on Activities of Daily Living
The Impact of Weight on Activities of Daily Living questionnaire (renamed the Ability to Perform Physical Activities of Daily Living Questionnaire \[APPADL\]) contains 7 items that assess how difficult it is for participants to engage in certain activities considered to be integral to normal daily life, such as walking, standing and climbing stairs. Items are scored on a 5-point numeric rating scale where 5 = "not at all difficult" and 1 = "unable to do". The individual scores from all 7 items are summed and a single total score is calculated and may range between 7 and 35. A higher score indicates better ability to perform activities of daily living. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.
Time frame: Baseline, 26, 52, and 78 weeks
Change From Baseline to 26, 52 and 78 Weeks in the Impact of Weight on Self-Perception
The Impact of Weight on Self-Perception (IW-SP) questionnaire contains 3 items that assess how often the participants' body weight affects how happy they are with their appearance and how often they feel self-conscious when out in public. Items are scored on a 5-point numeric rating scale where 5 = never and 1 = always. A single total score is calculated by summing the scores for all 3 items. Total score ranges between 3 and 15, where a higher score is indicative of better self-perception. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.
Time frame: Baseline, 26, 52, and 78 weeks
Change From Baseline to 26, 52 and 78 Weeks in the Low Blood Sugar Survey
The Low Blood Sugar Survey (LBSS) contains 33 items comprised of 2 subscales (behavior and worry), each of which is rated on a 5-point numeric rating scale from 0 (never) to 4 (almost always). It captures behavioral changes associated with the concerns and experiences of hypoglycemia and the degree to which participants are worried about certain aspects associated with hypoglycemia during the previous 4 weeks. The behavior (or avoidance) subscale has 15 items, and the worry (or affect) subscale has 18 items. Subscale scores are calculated by summing participant responses to items (behavior range 0-60; worry range 0-72). A total score is calculated as the sum of both subscales (range 0-132). Higher scores indicate greater negative impact on subscales and total score. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.
Time frame: Baseline, 26, 52, and 78 weeks
Number of Participants With Treatment Emergent Adverse Events at 26, 52 and 78 Weeks
A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with one or more TEAE is summarized cumulatively at 26, 52, and 78 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: 26, 52, and 78 weeks
Number of Self-reported Hypoglycemic Events at 26, 52 and 78 Weeks
Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of =\<3.9 mmol/L), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of =\<3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The number of self-reported hypoglycemic events is summarized cumulatively at 26, 52, and 78 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 26, 52, and 78 weeks
Rate of Self-reported Hypoglycemic Events at 26, 52 and 78 Weeks
Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of =\<3.9 mmol/L), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of =\<3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The 1-year adjusted rate of hypoglycemic events is summarized cumulatively at 26, 52, and 78 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 26, 52, and 78 weeks
Number of Participants Requiring Additional Intervention Due to Hyperglycemia at 26, 52 and 78 Weeks
Additional intervention was defined as any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation. The number of participants requiring additional intervention due to hyperglycemia is summarized cumulatively at 26, 52, and 78 weeks.
Time frame: 26, 52, and 78 weeks
Change From Baseline to 26, 52 and 78 Weeks on Pancreatic Enzymes
Amylase (total and pancreas-derived) and lipase concentrations were measured.
Time frame: Baseline, 26, 52, and 78 weeks
Number of Participants With Adjudicated Pancreatitis at 26, 52 and 78 Weeks
The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively at 26, 52, and 78 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 26, 52, and 78 weeks
Change From Baseline to 26, 52 and 78 Weeks on Serum Calcitonin
Time frame: Baseline, 26, 52, and 78 weeks
Number of Participants With Adjudicated Cardiovascular Events at 26, 52 and 78 Weeks
Information on cardiovascular (CV) risk factors was collected at baseline. Data on any new CV event was prospectively collected using a CV event electronic case report form. At prespecified visits, participants were asked about any new CV event. Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular AEs to be adjudicated include myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. The number of participants with adjudicated CV events is summarized cumulatively at 26, 52, and 78 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 26, 52, and 78 weeks
Change in Baseline to 26, 52 and 78 Weeks on Pulse Rate
Sitting pulse rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
Time frame: Baseline, 26, 52, and 78 weeks
Change From Baseline to 26, 52, and 78 Weeks on Blood Pressure
Sitting systolic blood pressure (SBP) and sitting diastolic blood pressure (DBP) were measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
Time frame: Baseline, 26, 52, and 78 weeks
Change From Baseline to 26, 52 and 78 Weeks on Electrocardiogram Parameters, Heart Rate
Electrocardiogram (ECG) heart rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
Time frame: Baseline, 26, 52, and 78 weeks
Change From Baseline to 26, 52 and 78 Weeks on Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval
The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
Time frame: Baseline, 26, 52, and 78 weeks
Number of Participants With LY2189265 Antibodies at 26, 52, 78 Weeks and 4 Weeks After Last Dose of Study Drug (83 Weeks Maximum)
LY2189265 (Dulaglutide) anti-drug antibodies (ADA) were assessed at baseline, 26, 52, and 78 weeks, and at the safety follow-up visit 30 days after study drug discontinuation (83 weeks). The number of participants with initial postbaseline detection of treatment emergent (defined as a 4-fold increase in the ADA titer from baseline) LY2189265 ADA at each time point were summarized.
Time frame: Baseline, 26, 52, 78, and 83 weeks
| Milestone | LY2189265 1.5 mg | LY2189265 0.75 mg | Insulin Glargine |
|---|---|---|---|
| Started | 273 | 272 | 265 |
| Received at least one dose of study drug | 273 | 272 | 262 |
| Completed | 242 | 243 | 238 |
| Not completed | 31 | 29 | 27 |
| Withdrew: Withdrawal by subject | 11 | 7 | 11 |
| Withdrew: Adverse event | 9 | 8 | 5 |
| Withdrew: Entry criteria not met | 3 | 2 | 0 |
| Withdrew: Lost to follow-up | 3 | 3 | 3 |
| Withdrew: Physician decision | 3 | 3 | 3 |
| Withdrew: Lack of efficacy | 1 | 1 | 0 |
| Withdrew: Treatment non-compliance | 1 | 2 | 2 |
| Withdrew: Protocol violation | 0 | 2 | 1 |
| Withdrew: Death | 0 | 1 | 2 |
Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline HbA1c as a covariate.
| percentage of glycosylated hemoglobin | LY2189265 1.5 mg | LY2189265 0.75 mg | Insulin Glargine |
|---|---|---|---|
| Change From Baseline to 52 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c) | -1.08 ± 0.06 | -0.76 ± 0.06 | -0.63 ± 0.06 |
Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline HbA1c as a covariate.
| percent | LY2189265 1.5 mg | LY2189265 0.75 mg | Insulin Glargine |
|---|---|---|---|
| 26 weeks (n=263, 266, 258) | -1.16 ± 0.06 | -0.89 ± 0.05 | -0.65 ± 0.06 |
| 78 weeks (n=263, 267, 259) | -0.90 ± 0.07 | -0.62 ± 0.07 | -0.59 ± 0.07 |
Number of participants achieving HbA1c levels less than 7.0% was analyzed with a logistic regression model with baseline, country, and treatment as factors included in the model.
| participants | LY2189265 1.5 mg | LY2189265 0.75 mg | Insulin Glargine |
|---|---|---|---|
| 26 weeks (n=263, 266, 258) | 153 | 122 | 84 |
| 52 weeks (n=263, 267, 259) | 140 | 99 | 80 |
| 78 weeks (n=263, 267, 259) | 129 | 91 | 79 |
Number of participants achieving HbA1c levels less than or equal to 6.5% was analyzed with a logistic regression model with baseline, country, and treatment as factors included in the model.
| participants | LY2189265 1.5 mg | LY2189265 0.75 mg | Insulin Glargine |
|---|---|---|---|
| 26 weeks (n=263, 266, 258) | 97 | 74 | 40 |
| 52 weeks (n=263, 267, 259) | 71 | 60 | 35 |
| 78 weeks (n=263, 267, 259) | 74 | 59 | 43 |
The self-monitored blood glucose (SMBG) data were collected at the following 8 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening meal; 2 hours post-evening meal; bedtime; and 3 AM or 5 hours after bedtime. Least Squares (LS) means of the mean of the 8 time points (Daily Mean) were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
| millimoles per liter (mmol/L) | LY2189265 1.5 mg | LY2189265 0.75 mg | Insulin Glargine |
|---|---|---|---|
| 26 weeks (n=199, 204, 190) | -1.79 ± 0.10 | -1.46 ± 0.10 | -1.58 ± 0.10 |
| 52 weeks (n=180, 185, 176) | -1.69 ± 0.11 | -1.32 ± 0.11 | -1.44 ± 0.11 |
| 78 weeks (n=172, 164, 168) | -1.55 ± 0.13 | -1.15 ± 0.12 | -1.47 ± 0.13 |
The homeostatic model assessment (HOMA) is a method used to quantify insulin resistance and beta (β)-cell function. HOMA2-B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady state beta cell function (%B) as a percentage of a normal reference population (normal young adults). HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S), as percentages of a normal reference population (normal young adults). The normal reference population for both HOMA2-B and HOMA-2S were set at 100%. Least Squares (LS) means of change from baseline of C-peptide based HOMA2-%B and HOMA2-%S were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
| percentage of HOMA2 | LY2189265 1.5 mg | LY2189265 0.75 mg |
|---|---|---|
| HOMA2-%B, 52 weeks (n=175, 181) | 29.95 ± 4.61 | 24.60 ± 4.51 |
| HOMA2-%B, 78 weeks (n=167, 165) | 28.54 ± 4.78 | 15.66 ± 4.75 |
| HOMA2-%S, 52 weeks (n=175,181) | -2.89 ± 1.21 | -2.66 ± 1.19 |
| HOMA2-%S, 78 weeks (n=167, 165) | -2.64 ± 1.23 | -3.62 ± 1.23 |
Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.
| picomoles per liter (pmol/L) | LY2189265 1.5 mg | LY2189265 0.75 mg | Insulin Glargine |
|---|---|---|---|
| 52 weeks (n=232, 231, 228) | -3.91 ± 0.47 | -3.31 ± 0.47 | -3.85 ± 0.47 |
| 78 weeks (n=235, 235, 232) | -3.57 ± 0.47 | -3.37 ± 0.47 | -3.65 ± 0.47 |
Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.
| kilogram (kg) | LY2189265 1.5 mg | LY2189265 0.75 mg | Insulin Glargine |
|---|---|---|---|
| 26 weeks | -1.82 ± 0.20 | -1.47 ± 0.20 | 1.01 ± 0.20 |
| 52 weeks | -1.87 ± 0.24 | -1.33 ± 0.24 | 1.44 ± 0.24 |
| 78 weeks | -1.96 ± 0.26 | -1.54 ± 0.26 | 1.28 ± 0.26 |
Body mass index (BMI) is an estimate of body fat based on body weight divided by height squared. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
| kilograms per square meter (kg/m^2) | LY2189265 1.5 mg | LY2189265 0.75 mg | Insulin Glargine |
|---|---|---|---|
| 26 weeks (n=257, 261, 245) | -0.64 ± 0.07 | -0.50 ± 0.07 | 0.44 ± 0.07 |
| 52 weeks (n=250, 252, 238) | -0.64 ± 0.08 | -0.39 ± 0.08 | 0.62 ± 0.08 |
| 78 weeks (n=246, 244, 238) | -0.64 ± 0.09 | -0.39 ± 0.09 | 0.59 ± 0.10 |
The European Quality of Life - 5 dimensions (EQ-5D) questionnaire is a generic, multidimensional, health-related, quality-of-life instrument. It consists of 2 parts: the first part assesses 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that have 3 possible levels of response (no problem, some problem, or extreme problem). These dimensions are converted into a weighted health-state Index Score. The EQ-5D United Kingdom (UK) score ranges from -0.59 to 1.0, where a score of 1.0 indicates perfect health and negative values are valued as worse than dead. The second part of the questionnaire consists of a 100-mm visual analog scale (VAS) on which the participants rated their perceived health state on that day from 0 (worst imaginable health state) to 100 (best imaginable health). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) and adjusted by treatment, country, and baseline.
| units on a scale | LY2189265 1.5 mg | LY2189265 0.75 mg | Insulin Glargine |
|---|---|---|---|
| EQ-5D UK, 26 weeks (n=257, 254, 249) | 0.01 ± 0.01 | 0.00 ± 0.01 | -0.01 ± 0.01 |
| EQ-5D UK, 52 weeks (n=259, 260, 253) | 0.01 ± 0.01 | 0.00 ± 0.01 | -0.04 ± 0.01 |
| EQ-5D UK, 78 weeks (n=259, 260, 253) | 0.01 ± 0.01 | 0.00 ± 0.01 | 0.00 ± 0.01 |
| VAS, 26 weeks (n=253, 252, 243) | 3.3 ± 0.83 | 3.4 ± 0.84 | 0.8 ± 0.86 |
| VAS, 52 weeks (n=260, 258, 252) | 3.2 ± 0.85 | 2.3 ± 0.85 | 1.1 ± 0.88 |
| VAS, 78 weeks (n=260, 258, 252) | 3.8 ± 0.85 | 3.2 ± 0.85 | 2.2 ± 0.89 |
The Impact of Weight on Activities of Daily Living questionnaire (renamed the Ability to Perform Physical Activities of Daily Living Questionnaire \[APPADL\]) contains 7 items that assess how difficult it is for participants to engage in certain activities considered to be integral to normal daily life, such as walking, standing and climbing stairs. Items are scored on a 5-point numeric rating scale where 5 = "not at all difficult" and 1 = "unable to do". The individual scores from all 7 items are summed and a single total score is calculated and may range between 7 and 35. A higher score indicates better ability to perform activities of daily living. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.
| units on a scale | LY2189265 1.5 mg | LY2189265 0.75 mg | Insulin Glargine |
|---|---|---|---|
| 26 weeks (n=256, 256, 248) | 0.7 ± 0.30 | 0.1 ± 0.30 | -0.3 ± 0.30 |
| 52 weeks (n=260, 261, 249) | 0.9 ± 0.31 | 0.4 ± 0.31 | -0.6 ± 0.32 |
| 78 weeks (n=260, 261, 249) | 1.0 ± 0.31 | 0.3 ± 0.31 | -0.3 ± 0.32 |
The Impact of Weight on Self-Perception (IW-SP) questionnaire contains 3 items that assess how often the participants' body weight affects how happy they are with their appearance and how often they feel self-conscious when out in public. Items are scored on a 5-point numeric rating scale where 5 = never and 1 = always. A single total score is calculated by summing the scores for all 3 items. Total score ranges between 3 and 15, where a higher score is indicative of better self-perception. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.
| units on a scale | LY2189265 1.5 mg | LY2189265 0.75 mg | Insulin Glargine |
|---|---|---|---|
| 26 weeks (n=258, 258, 251) | 0.1 ± 0.16 | 0.2 ± 0.16 | -0.1 ± 0.16 |
| 52 weeks (n=260, 261, 252) | 0.5 ± 0.16 | 0.2 ± 0.16 | 0.1 ± 0.16 |
| 78 weeks (n=260, 261, 252) | 0.5 ± 0.16 | 0.3 ± 0.15 | 0.1 ± 0.16 |
The Low Blood Sugar Survey (LBSS) contains 33 items comprised of 2 subscales (behavior and worry), each of which is rated on a 5-point numeric rating scale from 0 (never) to 4 (almost always). It captures behavioral changes associated with the concerns and experiences of hypoglycemia and the degree to which participants are worried about certain aspects associated with hypoglycemia during the previous 4 weeks. The behavior (or avoidance) subscale has 15 items, and the worry (or affect) subscale has 18 items. Subscale scores are calculated by summing participant responses to items (behavior range 0-60; worry range 0-72). A total score is calculated as the sum of both subscales (range 0-132). Higher scores indicate greater negative impact on subscales and total score. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.
| units on a scale | LY2189265 1.5 mg | LY2189265 0.75 mg | Insulin Glargine |
|---|---|---|---|
| 26 weeks (n=255, 255, 244) | -2.8 ± 0.95 | -2.4 ± 0.96 | 0.3 ± 0.98 |
| 52 weeks (n=258, 259, 245) | -4.2 ± 0.83 | -4.1 ± 0.83 | -1.0 ± 0.86 |
| 78 weeks (n=258, 259, 245) | -4.6 ± 0.82 | -4.7 ± 0.82 | -2.0 ± 0.85 |
A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with one or more TEAE is summarized cumulatively at 26, 52, and 78 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| participants | LY2189265 1.5 mg | LY2189265 0.75 mg | Insulin Glargine |
|---|---|---|---|
| 26 weeks | 160 | 146 | 137 |
| 52 weeks | 189 | 175 | 175 |
| 78 weeks | 201 | 188 | 192 |
Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of =\<3.9 mmol/L), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of =\<3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The number of self-reported hypoglycemic events is summarized cumulatively at 26, 52, and 78 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| events | LY2189265 1.5 mg | LY2189265 0.75 mg | Insulin Glargine |
|---|---|---|---|
| Severe HE, 26 weeks | 1 | 0 | 1 |
| Severe HE, 52 weeks | 1 | 0 | 2 |
| Severe HE, 78 weeks | 2 | 0 | 2 |
| Documented symptomatic HE, 26 weeks | 311 | 315 | 447 |
| Documented symptomatic HE, 52 weeks | 515 | 444 | 789 |
| Documented symptomatic HE, 78 weeks | 607 | 515 | 1033 |
| Asymptomatic HE, 26 weeks | 500 | 484 | 609 |
| Asymptomatic HE, 52 weeks | 757 | 709 | 1093 |
| Asymptomatic HE, 78 weeks | 884 | 911 | 1358 |
| Nocturnal HE, 26 weeks | 145 | 117 | 240 |
| Nocturnal HE, 52 weeks | 185 | 147 | 519 |
| Nocturnal HE, 78 weeks | 215 | 184 | 635 |
| Probable symptomatic HE, 26 weeks | 11 | 19 | 20 |
| Probable symptomatic HE, 52 weeks | 17 | 24 | 22 |
| Probable symptomatic HE, 78 weeks | 20 | 28 | 26 |
Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of =\<3.9 mmol/L), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of =\<3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The 1-year adjusted rate of hypoglycemic events is summarized cumulatively at 26, 52, and 78 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| events per participant per year | LY2189265 1.5 mg | LY2189265 0.75 mg | Insulin Glargine |
|---|---|---|---|
| Severe HE, 26 weeks | 0.01 ± 0.12 | 0.00 ± 0.00 | 0.01 ± 0.12 |
| Severe HE, 52 weeks | 0.00 ± 0.06 | 0.00 ± 0.00 | 0.01 ± 0.09 |
| Severe HE, 78 weeks | 0.01 ± 0.06 | 0.00 ± 0.00 | 0.01 ± 0.06 |
| Documented symptomatic HE, 26 weeks | 2.35 ± 5.41 | 2.52 ± 6.42 | 3.64 ± 6.63 |
| Documented symptomatic HE, 52 weeks | 2.03 ± 4.16 | 1.97 ± 5.31 | 3.34 ± 5.91 |
| Documented symptomatic HE, 78 weeks | 1.67 ± 3.58 | 1.66 ± 4.96 | 3.03 ± 5.63 |
| Asymptomatic HE, 26 weeks | 3.79 ± 8.01 | 3.58 ± 7.70 | 4.82 ± 11.43 |
| Asymptomatic HE, 52 weeks | 3.08 ± 6.97 | 2.68 ± 5.40 | 4.41 ± 8.72 |
| Asymptomatic HE, 78 weeks | 2.56 ± 5.90 | 2.38 ± 4.95 | 3.80 ± 7.24 |
| Nocturnal HE, 26 weeks | 1.23 ± 3.84 | 0.96 ± 3.53 | 1.86 ± 4.84 |
| Nocturnal HE, 52 weeks | 0.90 ± 3.13 | 0.65 ± 2.65 | 2.07 ± 4.67 |
| Nocturnal HE, 78 weeks | 0.77 ± 2.97 | 0.59 ± 2.47 | 1.81 ± 4.12 |
| Probable symptomatic HE, 26 weeks | 0.08 ± 0.59 | 0.14 ± 1.39 | 0.15 ± 0.87 |
| Probable symptomatic HE, 52 weeks | 0.07 ± 0.40 | 0.09 ± 0.99 | 0.08 ± 0.47 |
| Probable symptomatic HE, 78 weeks | 0.05 ± 0.32 | 0.07 ± 0.67 | 0.07 ± 0.37 |
Additional intervention was defined as any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation. The number of participants requiring additional intervention due to hyperglycemia is summarized cumulatively at 26, 52, and 78 weeks.
| participants | LY2189265 1.5 mg | LY2189265 0.75 mg | Insulin Glargine |
|---|---|---|---|
| 26 weeks | 2 | 4 | 0 |
| 52 weeks | 11 | 20 | 8 |
| 78 weeks | 24 | 34 | 16 |
Amylase (total and pancreas-derived) and lipase concentrations were measured.
| units/liter | LY2189265 1.5 mg | LY2189265 0.75 mg | Insulin Glargine |
|---|---|---|---|
| Amylase (total), 26 weeks | 4.000 (-4.000 to 13.000) | 4.000 (-3.000 to 11.000) | 2.000 (-5.000 to 8.000) |
| Amylase (total), 52 weeks | 4.000 (-4.000 to 11.000) | 5.000 (-3.000 to 13.000) | 3.000 (-5.000 to 9.000) |
| Amylase (total), 78 weeks | 4.000 (-4.000 to 13.000) | 4.000 (-3.000 to 12.000) | 1.000 (-7.000 to 9.000) |
| Amylase (pancreas-derived), 26 weeks | 3.000 (-1.000 to 8.000) | 3.000 (0.000 to 7.000) | 1.000 (-2.000 to 4.000) |
| Amylase (pancreas-derived), 52 weeks | 3.000 (-1.000 to 8.000) | 3.000 (-1.000 to 7.000) | 1.000 (-2.000 to 6.000) |
| Amylase (pancreas-derived), 78 weeks | 2.000 (-2.000 to 7.000) | 2.000 (-1.000 to 7.000) | 0.000 (-3.000 to 4.000) |
| Lipase, 26 weeks | 5.000 (-4.000 to 15.000) | 5.000 (-1.000 to 15.000) | -1.000 (-6.000 to 5.000) |
| Lipase, 52 weeks | 4.000 (-3.000 to 12.000) | 4.000 (-2.000 to 11.000) | -1.000 (-8.000 to 6.000) |
| Lipase, 78 weeks | 4.000 (-3.000 to 14.000) | 4.000 (-1.000 to 13.000) | -2.000 (-8.000 to 5.000) |
The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively at 26, 52, and 78 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| participants | LY2189265 1.5 mg | LY2189265 0.75 mg | Insulin Glargine |
|---|---|---|---|
| 26 weeks | 1 | 1 | 0 |
| 52 weeks | 2 | 1 | 0 |
| 78 weeks | 2 | 1 | 0 |
| picogram/milliliter | LY2189265 1.5 mg | LY2189265 0.75 mg | Insulin Glargine |
|---|---|---|---|
| 26 weeks (n=266, 267, 258) | 0.163 ± 1.31 | 0.097 ± 1.20 | 0.149 ± 1.30 |
| 52 weeks (n=266, 269, 259) | 0.128 ± 1.20 | 0.132 ± 1.32 | 0.176 ± 1.62 |
| 78 weeks (n=267, 269, 259) | 0.086 ± 1.31 | 0.035 ± 1.20 | 0.151 ± 1.73 |
Information on cardiovascular (CV) risk factors was collected at baseline. Data on any new CV event was prospectively collected using a CV event electronic case report form. At prespecified visits, participants were asked about any new CV event. Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular AEs to be adjudicated include myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. The number of participants with adjudicated CV events is summarized cumulatively at 26, 52, and 78 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| participants | LY2189265 1.5 mg | LY2189265 0.75 mg | Insulin Glargine |
|---|---|---|---|
| Any CV event, 26 weeks | 2 | 1 | 3 |
| Any fatal CV event, 26 weeks | 0 | 0 | 0 |
| Any non-fatal CV event, 26 weeks | 2 | 1 | 3 |
| Any CV event, 52 weeks | 3 | 4 | 6 |
| Any fatal CV event, 52 weeks | 0 | 0 | 1 |
| Any non-fatal CV event, 52 weeks | 3 | 4 | 5 |
| Any CV event, 78 week | 3 | 6 | 9 |
| Any fatal CV event, 78 week | 0 | 1 | 1 |
| Any non-fatal CV event, 78 week | 3 | 6 | 8 |
Sitting pulse rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
| beats per minute (bpm) | LY2189265 1.5 mg | LY2189265 0.75 mg | Insulin Glargine |
|---|---|---|---|
| 26 weeks (n=257, 260, 245) | 1.56 ± 0.49 | 0.74 ± 0.48 | -1.21 ± 0.50 |
| 52 weeks (n=250, 252, 240) | 1.29 ± 0.50 | 0.51 ± 0.49 | -0.52 ± 0.51 |
| 78 weeks (n=246, 244, 238) | 1.31 ± 0.50 | 0.61 ± 0.50 | -0.91 ± 0.51 |
Sitting systolic blood pressure (SBP) and sitting diastolic blood pressure (DBP) were measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
| milliliter of mercury (mmHG) | LY2189265 1.5 mg | LY2189265 0.75 mg | Insulin Glargine |
|---|---|---|---|
| SBP, 26 weeks (n=257, 261, 245) | -1.28 ± 0.78 | -1.60 ± 0.78 | -0.03 ± 0.80 |
| SBP, 52 weeks (n=250, 252, 240) | 0.17 ± 0.81 | 0.09 ± 0.80 | 0.51 ± 0.83 |
| SBP, 78 weeks (n=246, 244, 238) | -0.70 ± 0.85 | -0.59 ± 0.85 | 0.51 ± 0.87 |
| DBP, 26 weeks (n=257, 261, 245) | -0.16 ± 0.49 | -0.17 ± 0.48 | -0.29 ± 0.50 |
| DBP, 52 weeks (n=250, 252, 240) | -0.26 ± 0.48 | -0.19 ± 0.47 | -0.93 ± 0.49 |
| DBP, 78 weeks (n=246, 244, 238) | -0.44 ± 0.52 | -0.36 ± 0.52 | -1.04 ± 0.53 |
Electrocardiogram (ECG) heart rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
| beats per minute (bpm) | LY2189265 1.5 mg | LY2189265 0.75 mg | Insulin Glargine |
|---|---|---|---|
| 26 weeks (n=241, 247, 231) | 2.64 ± 0.539 | 0.90 ± 0.529 | -1.24 ± 0.549 |
| 52 weeks (n=232, 242, 231) | 2.41 ± 0.564 | 0.38 ± 0.551 | -1.01 ± 0.568 |
| 78 weeks (n=223, 222, 225) | 2.49 ± 0.592 | 0.47 ± 0.588 | -0.26 ± 0.594 |
The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
| milliseconds (msec) | LY2189265 1.5 mg | LY2189265 0.75 mg | Insulin Glargine |
|---|---|---|---|
| QTcF interval, 26 weeks (n=240, 245, 229) | -1.71 ± 0.939 | -0.10 ± 0.926 | 1.24 ± 0.962 |
| QTcF interval, 52 weeks (n=231, 240, 228) | 1.55 ± 1.074 | 1.34 ± 1.054 | 3.70 ± 1.088 |
| QTcF interval, 78 weeks (n=221, 220, 222) | 1.66 ± 1.045 | 3.44 ± 1.039 | 4.44 ± 1.053 |
| PR interval, 26 weeks (n=240, 245, 229) | 2.78 ± 0.849 | 2.33 ± 0.836 | 1.24 ± 0.873 |
| PR interval, 52 weeks (n=230, 240, 227) | 2.61 ± 0.853 | 1.88 ± 0.835 | 1.50 ± 0.868 |
| PR interval, 78 weeks (n=221, 220, 222) | 2.62 ± 1.034 | 3.27 ± 1.026 | 1.21 ± 1.043 |
LY2189265 (Dulaglutide) anti-drug antibodies (ADA) were assessed at baseline, 26, 52, and 78 weeks, and at the safety follow-up visit 30 days after study drug discontinuation (83 weeks). The number of participants with initial postbaseline detection of treatment emergent (defined as a 4-fold increase in the ADA titer from baseline) LY2189265 ADA at each time point were summarized.
| participants | LY2189265 1.5 mg and 0.75 mg |
|---|---|
| 26 weeks | 11 |
| 52 weeks | 3 |
| 78 weeks | 1 |
| 83 weeks | 0 |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LY2189265 1.5 mg | — | 32/273 (11.7%) | 199/273 (72.9%) |
| LY2189265 0.75 mg | — | 28/272 (10.3%) | 190/272 (69.9%) |
| Insulin Glargine | — | 33/262 (12.6%) | 187/262 (71.4%) |
| Event | LY2189265 1.5 mg | LY2189265 0.75 mg | Insulin Glargine |
|---|---|---|---|
| OverdoseInjury, poisoning and procedural complications | 3/273 | 0/272 | 0/262 |
| HyperglycaemiaMetabolism and nutrition disorders | 3/273 | 0/272 | 0/262 |
| Maternal exposure during pregnancyInjury, poisoning and procedural complications | 0/129 | 0/136 | 1/128 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/129 | 0/136 | 1/128 |
| Coronary artery diseaseCardiac disorders | 1/273 | 0/272 | 2/262 |
| CholelithiasisHepatobiliary disorders | 1/273 | 1/272 | 2/262 |
| HypoglycaemiaMetabolism and nutrition disorders | 2/273 | 0/272 | 2/262 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/273 | 0/272 | 2/262 |
| Acute myocardial infarctionCardiac disorders | 0/273 | 2/272 | 0/262 |
| Angina unstableCardiac disorders | 0/273 | 2/272 | 0/262 |
| Event | LY2189265 1.5 mg | LY2189265 0.75 mg | Insulin Glargine |
|---|---|---|---|
| NauseaGastrointestinal disorders | 42/273 | 22/272 | 4/262 |
| DiarrhoeaGastrointestinal disorders | 29/273 | 26/272 | 15/262 |
| NasopharyngitisInfections and infestations | 16/273 | 12/272 | 24/262 |
| HeadacheNervous system disorders | 22/273 | 9/272 | 13/262 |
| DyspepsiaGastrointestinal disorders | 19/273 | 9/272 | 6/262 |
| VomitingGastrointestinal disorders | 18/273 | 10/272 | 3/262 |
| Upper respiratory tract infectionInfections and infestations | 15/273 | 11/272 | 17/262 |
| Urinary tract infectionInfections and infestations | 12/273 | 17/272 | 15/262 |
| BronchitisInfections and infestations | 9/273 | 7/272 | 14/262 |
| InfluenzaInfections and infestations | 12/273 | 13/272 | 14/262 |
Participants who were randomized and received at least 1 dose of LY2189265 or Insulin Glargine.
| Age, Continuous(years) | LY2189265 1.5 mg | LY2189265 0.75 mg | Insulin Glargine | Total |
|---|---|---|---|---|
| Mean | 56.24 ± 9.76 | 56.56 ± 9.27 | 57.21 ± 9.38 | 56.66 ± 9.47 |
| Sex: Female, Male(Participants) | LY2189265 1.5 mg | LY2189265 0.75 mg | Insulin Glargine | Total |
|---|---|---|---|---|
| Female | 129 | 136 | 128 | 393 |
| Male | 144 | 136 | 134 | 414 |
| Ethnicity (NIH/OMB)(Participants) | LY2189265 1.5 mg | LY2189265 0.75 mg | Insulin Glargine | Total |
|---|---|---|---|---|
| Hispanic or Latino | 98 | 96 | 97 | 291 |
| Not Hispanic or Latino | 175 | 176 | 165 | 516 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | LY2189265 1.5 mg | LY2189265 0.75 mg | Insulin Glargine | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 29 | 31 | 29 | 89 |
| Asian | 48 | 46 | 43 | 137 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 2 | 4 |
| White | 193 | 193 | 184 | 570 |
| More than one race | 2 | 1 | 4 | 7 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | LY2189265 1.5 mg | LY2189265 0.75 mg | Insulin Glargine | Total |
|---|---|---|---|---|
| Taiwan | 13 | 13 | 12 | 38 |
| Slovakia | 1 | 1 | 0 | 2 |
| Greece | 6 | 6 | 7 | 19 |
| Spain | 10 | 12 | 13 | 35 |
| Italy | 2 | 3 | 1 | 6 |
| India | 30 | 27 | 27 | 84 |
| France | 2 | 3 | 1 | 6 |
| Czech Republic | 12 | 14 | 13 | 39 |
| Hungary | 16 | 16 | 15 | 47 |
| Mexico | 29 | 28 | 27 | 84 |
| Canada | 26 | 25 | 24 | 75 |
| Argentina | 55 | 54 | 54 | 163 |
| Belgium | 7 | 5 | 3 | 15 |
| Brazil | 6 | 5 | 7 | 18 |
| Poland | 16 | 18 | 17 | 51 |
| Croatia | 3 | 4 | 4 | 11 |
| Romania | 23 | 22 | 22 | 67 |
| Australia | 13 | 13 | 13 | 39 |
| Sweden | 2 | 0 | 1 | 3 |
| Korea, Republic of | 1 | 3 | 1 | 5 |
| Body Weight(kilograms) | LY2189265 1.5 mg | LY2189265 0.75 mg | Insulin Glargine | Total |
|---|---|---|---|---|
| Mean | 85.13 ± 17.90 | 86.18 ± 18.15 | 87.66 ± 19.62 | 86.31 ± 18.56 |
| Body Mass Index (BMI)(kilograms per square meter (kg/m^2)) | LY2189265 1.5 mg | LY2189265 0.75 mg | Insulin Glargine | Total |
|---|---|---|---|---|
| Mean | 31.23 ± 5.21 | 31.51 ± 5.41 | 31.91 ± 5.76 | 31.55 ± 5.46 |
| Glycosylated Hemoglobin (HbA1c)(percentage of glycosylated hemoglobin) | LY2189265 1.5 mg | LY2189265 0.75 mg | Insulin Glargine | Total |
|---|---|---|---|---|
| Mean | 8.18 ± 1.03 | 8.13 ± 0.98 | 8.10 ± 0.95 | 8.14 ± 0.99 |
2 further baseline measures are reported on the registry.
The record gives a start of Feb 2010, a primary completion of May 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2015, 2 years 8 months after primary completion. A results delay was requested in Sep 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dulaglutide